Lasofoxifene is a new-generation selective estrogen receptor modulator that completed the Phase III development program for the prevention and treatment of osteoporosis in postmenopausal women. This compound has a remarkably improved oral bioavailability with respect to other selective estrogen receptor modulators owing to its increased resistance to intestinal wall glucuronidation. In both preclinical and short-term Phase II clinical studies, lasofoxifene showed a favorable safety profile and demonstrated a proven efficacy in preventing bone loss and lowering cholesterol levels. The recent results from Phase III clinical trials demonstrated the clinical efficacy of this drug in the prevention of vertebral and nonvertebral fractures. The purpose of this article is to review the clinical evidence for the use of lasofoxifene in women after menopause and to discuss how it will fit into the treatment of postmenopausal osteoporosis. © 2009, Expert Reviews Ltd. All rights reserved.
Gennari, L., Merlotti, D., Nuti, R. (2009). Lasofoxifene: a new-generation SERM for the treatment of postmenopausal osteoporosis. EXPERT REVIEW OF OBSTETRICS & GYNECOLOGY, 4(6), 607-617 [10.1586/EOG.09.55].
Lasofoxifene: a new-generation SERM for the treatment of postmenopausal osteoporosis
GENNARI, LUIGI;MERLOTTI, DANIELA;NUTI, RANUCCIO
2009-01-01
Abstract
Lasofoxifene is a new-generation selective estrogen receptor modulator that completed the Phase III development program for the prevention and treatment of osteoporosis in postmenopausal women. This compound has a remarkably improved oral bioavailability with respect to other selective estrogen receptor modulators owing to its increased resistance to intestinal wall glucuronidation. In both preclinical and short-term Phase II clinical studies, lasofoxifene showed a favorable safety profile and demonstrated a proven efficacy in preventing bone loss and lowering cholesterol levels. The recent results from Phase III clinical trials demonstrated the clinical efficacy of this drug in the prevention of vertebral and nonvertebral fractures. The purpose of this article is to review the clinical evidence for the use of lasofoxifene in women after menopause and to discuss how it will fit into the treatment of postmenopausal osteoporosis. © 2009, Expert Reviews Ltd. All rights reserved.File | Dimensione | Formato | |
---|---|---|---|
Gennari DP.pdf
non disponibili
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
336.74 kB
Formato
Adobe PDF
|
336.74 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/41287
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo